Table 8.

Mean (IU/L) ± standard deviation serum amylase and lipase values through Week 156

Week	Serum amylase		Serum lipase
	Omarigliptin N = 2092	Placebo N = 2100	Omarigliptin N = 2092	Placebo N = 2100
0	66.5 ± 33.3 n = 1465	67.5 ± 39.2 n = 1457	45.1 ± 35.4 n = 1465	45.5 ± 53.5 n = 1457
6	71.3 ± 34.0 n = 1353	66.7 ± 35.1 n = 1338	53.4 ± 45.6 n = 1353	45.1 ± 50.1 n = 1337
12	72.9 ± 35.8 n = 1329	68.1 ± 42.7 n = 1301	56.2 ± 49.9 n = 1329	46.4 ± 41.7 n = 1300
18	71.6 ± 35.3 n = 1314	67.4 ± 35.2 n = 1281	52.1 ± 42.2 n = 1313	45.1 ± 39.0 n = 1280
24	72.0 ± 34.8 n = 1305	67.6 ± 33.4 n = 1296	55.6 ± 52.5 n = 1305	45.5 ± 35.0 n = 1295
32	71.3 ± 33.7 n = 1308	68.1 ± 34.8 n = 1292	51.4 ± 33.2 n = 1308	46.4 ± 42.9 n = 1292
40	70.9 ± 35.4 n = 1289	67.1 ± 33.8 n = 1261	51.3 ± 37.5 n = 1289	43.7 ± 29.3 n = 1261
48	71.6 ± 34.6 n = 1282	67.5 ± 35.9 n = 1235	54.2 ± 54.2 n = 1280	44.6 ± 36.1 n = 1236
54	74.1 ± 52.6 n = 1292	68.2 ± 33.5 n = 1253	56.3 ± 185.2 n = 1291	44.1 ± 37.9 n = 1253
66	72.8 ± 35.8 n = 1263	68.8 ± 42.4 n = 1229	54.3 ± 56.3 n = 1260	44.5 ± 37.1 n = 1229
78	75.1 ± 57.9 n = 1339	67.5 ± 33.9 n = 1297	53.4 ± 50.2 n = 1339	47.2 ± 61.9 n = 1294
90	72.1 ± 38.0 n = 836	69.1 ± 38.8 n = 808	57.4 ± 74.0 n = 835	46.1 ± 40.5 n = 808
104	74.8 ± 85.9 n = 612	68.3 ± 42.1 n = 568	72.3 ± 437.2 n = 611	45.1 ± 32.6 n = 568
116	74.7 ± 38.2 n = 376	65.5 ± 30.8 n = 351	59.0 ± 84.0 n = 376	46.6 ± 54.2 n = 351
128	75.7 ± 36.2 n = 213	64.1 ± 32.7 n = 223	58.4 ± 52.6 n = 213	42.9 ± 24.5 n = 223
142	70.7 ± 30.8 n = 69	71.7 ± 54.2 n = 55	52.8 ± 31.2 n = 69	44.0 ± 25.9 n = 55
156	70.0 ± N/A n = 1	41.0 ± N/A n = 1	31.0 ± N/A n = 1	9.0 ± N/A n = 1

Measurement of amylase and lipase was added to the protocol after study initiation at the request of several European countries; therefore not all patients had baseline values

Central laboratory normal range: serum amylase = 35–121 U/L; serum lipase = 13–60 U/L